Mainz Biomed (MYNZ) Competitors $4.89 +0.23 (+4.94%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$4.91 +0.02 (+0.41%) As of 03/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends MYNZ vs. FBLG, ME, LTRN, ATRA, PRLD, DTIL, BRNS, FGEN, GRCE, and BLUEShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include FibroBiologics (FBLG), 23andMe (ME), Lantern Pharma (LTRN), Atara Biotherapeutics (ATRA), Prelude Therapeutics (PRLD), Precision BioSciences (DTIL), Barinthus Biotherapeutics (BRNS), FibroGen (FGEN), Grace Therapeutics (GRCE), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. FibroBiologics 23andMe Lantern Pharma Atara Biotherapeutics Prelude Therapeutics Precision BioSciences Barinthus Biotherapeutics FibroGen Grace Therapeutics bluebird bio FibroBiologics (NASDAQ:FBLG) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate FBLG or MYNZ? FibroBiologics presently has a consensus price target of $13.00, indicating a potential upside of 1,126.42%. Mainz Biomed has a consensus price target of $14.00, indicating a potential upside of 186.30%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe FibroBiologics is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Mainz Biomed 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community prefer FBLG or MYNZ? Mainz Biomed received 4 more outperform votes than FibroBiologics when rated by MarketBeat users. However, 100.00% of users gave FibroBiologics an outperform vote while only 73.68% of users gave Mainz Biomed an outperform vote. CompanyUnderperformOutperformFibroBiologicsOutperform Votes10100.00% Underperform VotesNo VotesMainz BiomedOutperform Votes1473.68% Underperform Votes526.32% Which has more volatility & risk, FBLG or MYNZ? FibroBiologics has a beta of -0.7, meaning that its share price is 170% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Which has higher earnings & valuation, FBLG or MYNZ? FibroBiologics has higher earnings, but lower revenue than Mainz Biomed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroBiologicsN/AN/A-$16.49MN/AN/AMainz Biomed$917.20K10.67-$26.30M-$65.60-0.07 Is FBLG or MYNZ more profitable? Company Net Margins Return on Equity Return on Assets FibroBiologicsN/A N/A -225.34% Mainz Biomed N/A N/A N/A Does the media prefer FBLG or MYNZ? In the previous week, Mainz Biomed had 1 more articles in the media than FibroBiologics. MarketBeat recorded 2 mentions for Mainz Biomed and 1 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 1.89 beat Mainz Biomed's score of 1.87 indicating that FibroBiologics is being referred to more favorably in the media. Company Overall Sentiment FibroBiologics Very Positive Mainz Biomed Very Positive SummaryFibroBiologics beats Mainz Biomed on 7 of the 12 factors compared between the two stocks. Remove Ads Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.79M$6.94B$5.64B$8.08BDividend YieldN/A2.72%4.89%4.04%P/E Ratio-0.076.1223.7418.99Price / Sales10.67226.08381.75120.64Price / CashN/A65.6738.0534.64Price / Book0.456.656.904.26Net Income-$26.30M$139.34M$3.18B$247.00M7 Day Performance-10.28%-0.50%6.75%-1.60%1 Month Performance-25.11%-7.34%0.16%-9.68%1 Year Performance-88.47%-4.34%13.61%1.96% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed3.0722 of 5 stars$4.89+4.9%$14.00+186.3%-88.6%$9.79M$917,203.00-0.0730Short Interest ↓FBLGFibroBiologics2.5127 of 5 stars$1.14-9.2%$13.00+1,036.4%-91.5%$41.65MN/A0.0010Positive NewsME23andMe1.4498 of 5 stars$1.55-29.8%$9.40+508.4%-82.3%$41.42M$208.78M-0.10770Short Interest ↑High Trading VolumeLTRNLantern Pharma0.5549 of 5 stars$3.82-3.3%N/A-50.1%$41.25MN/A-2.1520Upcoming EarningsPositive NewsATRAAtara Biotherapeutics3.9695 of 5 stars$7.01+1.4%$17.75+153.2%-60.6%$40.38M$100.44M-0.27330Earnings ReportAnalyst ForecastPRLDPrelude Therapeutics3.1567 of 5 stars$0.72-4.6%$4.00+452.5%-83.0%$39.90M$3M-0.41120Earnings ReportShort Interest ↓News CoverageGap UpDTILPrecision BioSciences4.01 of 5 stars$5.20-3.5%$37.67+624.4%-57.9%$39.89M$75.10M86.68200BRNSBarinthus Biotherapeutics2.9582 of 5 stars$0.99-2.5%$5.17+424.5%-58.5%$39.63M$14.97M-0.66107Upcoming EarningsShort Interest ↓News CoverageFGENFibroGen4.0465 of 5 stars$0.39-5.0%$10.00+2,477.3%-75.6%$39.10M$180.02M-0.32570Upcoming EarningsShort Interest ↑Gap DownGRCEGrace Therapeutics2.5593 of 5 stars$2.87-5.3%$12.00+318.1%N/A$38.51MN/A-2.47N/ABLUEbluebird bio2.641 of 5 stars$3.91-4.2%$44.14+1,029.0%-85.7%$38.01M$53.12M-0.10520Analyst ForecastShort Interest ↓ Remove Ads Related Companies and Tools Related Companies FibroBiologics Alternatives 23andMe Alternatives Lantern Pharma Alternatives Atara Biotherapeutics Alternatives Prelude Therapeutics Alternatives Precision BioSciences Alternatives Barinthus Biotherapeutics Alternatives FibroGen Alternatives Grace Therapeutics Alternatives bluebird bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts